When you come out of the storm, you won’t be the same person who walked in. That’s what this storm’s all about.” ? Haruki Murakami, Kafka on the Shore
Today, we take a look at a name in the biotech sector that does not get much cover despite a sizable market cap.
Company Overview:
XBiotech (XBIT) IPO’d in 2015 and is an Austin, Texas-based clinical-stage biopharmaceutical company focused on developing TrueHuman monoclonal antibodies for treating a bevy of diseases. TrueHuman monoclonal antibodies differ from animal immunization or otherwise engineered monoclonal antibodies in